MedPath

Role of omega- 3 fatty acids in the treatment of periodontal diseases

Phase 3
Conditions
Health Condition 1: K053- Chronic periodontitis
Registration Number
CTRI/2022/12/047945
Lead Sponsor
DR DEVISREE RV
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

i.Periodontally healthy individuals, patients with generalized gingivitis as well as generalized periodontitis diagnosed according to criteria given by American Academy of Periodontology 2017 classification15.

ii.Patients belonging to both sexes who are willing to participate in the study.

Exclusion Criteria

I.Pregnant and lactating females

II.Periodontal or orthodontic treatment at least 6 months before the start of the study

III.SRP as part of initial periodontal therapy within the past 6 months

IV.smokers, history of diabetes, radiation therapy, chemotherapy or patients on corticosteroid therapy.

V.any diseases or disorders that compromise wound healing,

VI.any history of chronic inflammatory disease and any oral mucosal inflammatory condition (e.g., aphthous, lichen planus);

VII.Use of antibiotics, corticosteroids and antiâ??inflammatory drugs within 3 months before sampling.

VIII.Patients on regular use of any nutritional supplements which can affect the study outcome

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
â?¢% Reduction in number of periodontal pockets with PPD â?¥ 4mm with bleeding on probing in group treated with adjunctive use of omega 3 PUFA and nonsurgical periodontal therapy alone. <br/ ><br> <br/ ><br> <br/ ><br>Timepoint: 0,3,6 months <br/ ><br>
Secondary Outcome Measures
NameTimeMethod
salivary levels of lipoxin A4 measured using ELISA in group treated with adjunctive use of omega 3 PUFA and nonsurgical periodontal therapy aloneTimepoint: 0,6 months
© Copyright 2025. All Rights Reserved by MedPath